Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial intelligence technologies. With its proprietary platform, the firm streamlines the design, optimization, and production of therapeutic proteins, significantly enhancing the efficiency of the drug discovery process while lowering associated costs. Boasting a robust pipeline and strategic partnerships with leading industry players, Generate Biomedicines is poised to deliver groundbreaking treatments that tackle pressing healthcare issues and enhance patient outcomes across multiple therapeutic domains.
| Revenue (TTM) | $26.48M |
| Gross Profit (TTM) | $-213.80M |
| EBITDA | $-249.55M |
| Operating Margin | -1134.00% |
| Return on Equity | -81.70% |
| Return on Assets | -34.60% |
| Revenue/Share (TTM) | $0.32 |
| Book Value | $3.56 |
| Price-to-Book | 4.65 |
| Price-to-Sales (TTM) | 77.50 |
| EV/Revenue | 65.16 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -37.70% |
| Shares Outstanding | $128.35M |
| Float | $60.45M |
| % Insiders | 14.05% |
| % Institutions | 77.59% |
Volatility is currently contracting
Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor conferences:
Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares issued as part of Generate's $400 million initial public offering earlier this year, which included 25 million shares.
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer) Platform advancements extend across strategic collaborations Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026 SOMERVILLE, Mass.
Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced that AdvanCell has signed a long-term ~128,000 square foot lease for the entire 1 Corporate Drive building at Innovation Park, IQHQ's premier life science and advanced manufacturing campus in Andover, Massachusetts. The transaction is one of the largest life science leases in Greater Boston this year and brings the newly constructed Phase 2 of Innovation Park to 100% leased.
SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026.
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GENB and any ticker you trade — then tracks every position and per-strategy win rate.
